These effects were potentially overlooked in previous studies in which the experimental design was based on lean mice on a standard laboratory diet rather than models of dyslipidemia and atherosclerosis.9–12,14–18 Off target activation of PXR or (hepato)toxicity did not underlie the metabolic effects of ONX-0914 treatment. The gene discussed is NR1I2; the disease is metabolic syndrome.